혈액은행 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the blood bank market size is expected to reach USD 24.32 billion in 2026 and is projected to reach USD 32.29 billion by 2031, reflecting a CAGR of 5.85% over the forecast period.

This report is Segmented by Product (Whole Blood, Red Blood Cells [Packed RBC, and More], Platelets, Plasma, and More), Function (Collection, Processing, Testing, and More), Bank Type (Private and Public), End User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts is Provided in Terms of Value (USD).

Global Blood Bank Market Trends and Insights

Rising Number of Surgeries & Road-Traffic Accidents

Global surgical volume climbed 7.3% in 2024, led by joint arthroplasty and cardiac revascularization, each consuming nearly 2 units of packed red blood cells per case. Road-traffic injuries caused 1.19 million deaths in 2024, triggering massive-transfusion protocols that demand up to 10 units of RBCs within the first hour . India's 2024 survey of 89 trauma centers showed 42% lacked emergency O-negative reserves, delaying definitive surgery. Mobile collection teams and pre-hospital triage are easing the mismatch, yet infrastructure lags population growth in Sub-Saharan Africa and Southeast Asia. Minimally invasive techniques reduce per-case usage but are offset by the sheer rise in procedures as healthcare access broadens.

Growing Prevalence of Hematologic & Oncologic Disorders

The United States recorded 2.04 million new cancer diagnoses in 2024, with up to half of acute leukemia patients requiring prophylactic platelet support . Chronic lymphocytic leukemia and multiple myeloma cohorts expanded 18% in Europe between 2020 and 2024, intensifying plasma-derived immunoglobulin demand. Sickle-cell disease still drives 8-12 transfusions per patient annually despite gene-therapy approvals, while thalassemia maintains chronic demand across South and Southeast Asia. Clinicians increasingly select pathogen-reduced platelets for immunocompromised recipients, absorbing higher per-unit costs in exchange for lower infection risk.

Stringent Regulatory Compliance & Accreditation Costs

AABB's 34th-edition standards added 47 new requirements, compelling U.S. centers to spend USD 1.2-3.5 million on software, audits, and training. FDA inspections under 21 CFR 606 carry penalties of up to USD 500,000 per violation, prompting 18 small banks to merge since 2022. In Europe, the 2024 Blood Directive amendment lifted operating costs by 8-12%. Rural African banks struggle with ISO 9001 fees exceeding USD 50,000, limiting access to accredited supply. Additional donor-deferral rules for malaria travel further tighten eligibility in multicultural urban centers.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Voluntary Non-Remunerated Donation Programs
2. Rapid Adoption of Pathogen-Reduction Technologies (PRTs)
3. Shrinking Donor Base in High-Income Nations

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Plasma-derived products are forecast to grow at an 8.32% CAGR, the quickest among product categories, while red blood cells maintained a 42.5% blood bank market share in 2025. Immunoglobulins for primary immunodeficiency and CIDP consumed two-thirds of U.S. plasma output in 2024, driving aggressive collection by Grifols and CSL Plasma. Pathogen-reduced plasma captured 18% of European hospital demand in 2025 as infection-control standards rose. Platelet supply remains constrained by a five-day shelf life, spurring AI-guided demand forecasts that cut outdating up to 25%. Whole blood now represents less than 8% of high-income-country collections, retained mainly for military stockpiles and low-resource settings.

Specialty components such as leukoreduced and irradiated RBCs command premiums but strain small-hospital capacity. Leukoreduction is standard in most of Europe and Canada, covering 92% of U.S. stock in 2024. Pathogen-reduced red blood cells entered U.S. pilot programs in 2025, and vendors aim for 15% penetration by 2031 as reimbursement stabilizes.

Collection is the fastest-growing function at a 7.87% CAGR, thanks to apheresis technology that returns RBCs to donors and yields higher-dose platelets. Haemonetics' MCS+ cut procedure time to 78 minutes, boosting donor retention by 9%. Testing accounted for 39.8% of 2025 revenue as NAT for HIV, HBV, and HCV remains compulsory under U.S. and EU rules. High-throughput devices dropped the cost per assay from USD 18 to USD 12, though new Zika and West Nile panels add USD 25-40 per donation. Processing is consolidating into regional hubs that handle up to 3,000 units per day, while automated logistics and blockchain traceability shorten inter-facility transport times by 18% in India.

Complete Report Scope:

• By Product
  • Whole Blood
  • Red Blood Cells (RBCs)
    • Packed RBC
    • Leukoreduced RBC
    • Irradiated RBC
  • Platelets
    • Pooled Platelets
    • Apheresis Platelets
    • Pathogen-Reduced Platelets
  • Plasma
    • Fresh-Frozen Plasma (FFP)
    • Cryoprecipitate
    • Pathogen-Reduced Plasma
  • White Blood Cells & Buffy Coat Products
  • Specialty Components
    • Deglycerolised RBC
    • Washed Platelets
• By Function
  • Collection
  • Processing
  • Testing
  • Storage
  • Transportation
• By Bank Type
  • Private
  • Public
• By End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialised Haematology & Oncology Clinics
  • Military & Emergency Medical Services
  • Research & Academic Institutes
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 45.32% of 2025 revenue, anchored by Medicare reimbursement for patient blood-management programs and rigorous FDA oversight. Donor recruitment, however, is faltering; 18-24-year-old participation dropped 11% from 2020 to 2024, prompting the adoption of AI inventory tools that trim wastage by up to 25%. Canada boasts a 3.8% voluntary-donor rate, yet 52% of donors are over 50, elevating deferral risk. Cerus' FDA approval for pathogen-reduced RBCs placed 22 U.S. trauma centers at the forefront of PRT rollouts.

Asia-Pacific is the fastest-growing region with a 7.21% CAGR forecast. China's push to 20 donations per 1,000 citizens and India's blockchain registry underpin robust volume growth despite cold-chain gaps in rural districts. Japan raised its donor age limit to 74 years in 2025 to counter a 4.1% donor pool contraction. South Korea's mandatory high-school education program lifted donations to 2.9 million units in 2024, though platelet shortages persist outside major metros.

Europe held about 28% of 2025 revenue but faces structural donor declines as the median age approaches 45 years. France pathogen-reduces all platelets, and Germany mandated PRT for immunocompromised facilities in 2025, adding USD 150-250 per platelet dose. The U.K. saw donations fall 3.2% in 2024, triggering a GBP 12 million investment in mobile-app scheduling and social-media outreach. Cold-chain weaknesses in MEA and South America contribute to 12% RBC spoilage, with Brazil relying on emergency appeals during Carnival season.

1. American Association of Blood Banks
2. American Red Cross
3. Australian Red Cross Lifeblood
4. BioLife Plasma Services (Takeda)
5. Blood Bank of Alaska
6. Canadian Blood Services
7. Cerus
8. CSL Plasma
9. Fresenius
10. Grifols
11. Haemonetics
12. Immucor
13. New York Blood Center (NYBC)
14. NHS Blood & Transplant (NHSBT)
15. Octapharma Plasma
16. Sanquin Blood Supply Foundation
17. Vitalant
18. Wuhan Plasma Plant

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Number of Surgeries & Road-Traffic Accidents
  • 4.2.2 Growing Prevalence of Hematologic & Oncologic Disorders
  • 4.2.3 Expansion Of Voluntary, Non-Remunerated Blood-Donation Programs
  • 4.2.4 Rapid Adoption of Pathogen-Reduction Technologies (PRTS)
  • 4.2.5 AI-Driven Inventory Optimization & Demand Forecasting
  • 4.2.6 Development Of On-Site Blood-Component Micro-Factories
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Compliance & Accreditation Costs
  • 4.3.2 Shrinking Donor Base in High-Income Nations
  • 4.3.3 Cold-Chain Vulnerabilities in Emerging Markets
  • 4.3.4 Competition From Synthetic & Recombinant Blood Substitutes
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Whole Blood
  • 5.1.2 Red Blood Cells (RBCs)
    • 5.1.2.1 Packed RBC
    • 5.1.2.2 Leukoreduced RBC
    • 5.1.2.3 Irradiated RBC
  • 5.1.3 Platelets
    • 5.1.3.1 Pooled Platelets
    • 5.1.3.2 Apheresis Platelets
    • 5.1.3.3 Pathogen-Reduced Platelets
  • 5.1.4 Plasma
    • 5.1.4.1 Fresh-Frozen Plasma (FFP)
    • 5.1.4.2 Cryoprecipitate
    • 5.1.4.3 Pathogen-Reduced Plasma
  • 5.1.5 White Blood Cells & Buffy Coat Products
  • 5.1.6 Specialty Components
    • 5.1.6.1 Deglycerolised RBC
    • 5.1.6.2 Washed Platelets
• 5.2 By Function
  • 5.2.1 Collection
  • 5.2.2 Processing
  • 5.2.3 Testing
  • 5.2.4 Storage
  • 5.2.5 Transportation
• 5.3 By Bank Type
  • 5.3.1 Private
  • 5.3.2 Public
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Ambulatory Surgical Centres
  • 5.4.3 Specialised Haematology & Oncology Clinics
  • 5.4.4 Military & Emergency Medical Services
  • 5.4.5 Research & Academic Institutes
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 American Association of Blood Banks (AABB)
  • 6.3.2 American Red Cross
  • 6.3.3 Australian Red Cross Lifeblood
  • 6.3.4 BioLife Plasma Services (Takeda)
  • 6.3.5 Blood Bank of Alaska
  • 6.3.6 Canadian Blood Services
  • 6.3.7 Cerus Corporation
  • 6.3.8 CSL Plasma
  • 6.3.9 Fresenius Kabi
  • 6.3.10 Grifols S.A.
  • 6.3.11 Haemonetics Corporation
  • 6.3.12 Immucor Inc.
  • 6.3.13 New York Blood Center (NYBC)
  • 6.3.14 NHS Blood & Transplant (NHSBT)
  • 6.3.15 Octapharma Plasma
  • 6.3.16 Sanquin Blood Supply Foundation
  • 6.3.17 Vitalant
  • 6.3.18 Wuhan Plasma Plant

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment